Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy …
M Packer - Circulation, 2022 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …
on the evolution and progression of cardiomyopathy and nephropathy, which is …
Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease
CJ Bailey, C Day, S Bellary - Current diabetes reports, 2022 - Springer
Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …
Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes
M Packer, CS Wilcox, JM Testani - Circulation, 2023 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF
L Shen, SL Kristensen, O Bengtsson, M Böhm… - Heart Failure, 2021 - jacc.org
Objectives The purpose of this study was to assess the efficacy and safety of dapagliflozin in
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …
Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism
J Tang, L Ye, Q Yan, X Zhang, L Wang - Frontiers in pharmacology, 2022 - frontiersin.org
Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects
by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently …
by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently …
Reno-and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
X Chen, CF Hocher, L Shen… - American Journal of …, 2023 - journals.physiology.org
Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …
Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial
S Gullaksen, L Vernstrøm, SS Sørensen, S Ringgaard… - Diabetologia, 2023 - Springer
Aims/hypothesis Glucagon-like peptide-1 receptor agonists (GLP-1ras) and sodium–glucose
cotransporter 2 inhibitors (SGLT2is) have shown kidney-protective effects. Improved kidney …
cotransporter 2 inhibitors (SGLT2is) have shown kidney-protective effects. Improved kidney …
Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial
JC Laursen, N Søndergaard-Heinrich… - …, 2021 - thelancet.com
Background Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression
of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with …
of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with …
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
M Packer - European Heart Journal, 2023 - academic.oup.com
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major heart
failure events, an action that is statistically linked to enhanced erythropoiesis, suggesting …
failure events, an action that is statistically linked to enhanced erythropoiesis, suggesting …